A new metric to understand the association between heart rate variability and menstrual regularity

Background

Cardiovascular disease (CVD) is the leading cause of death for women1. Compared to men, women receive lower quality care in relation to cardiovascular concerns and are consistently underrepresented in cardiovascular research2,3,4. Accordingly, current understanding of the impacts of the menstrual cycle on female cardiovascular health remains limited5. For example, women experiencing irregular menstrual cycles have a higher risk of coronary heart disease, cancer, and osteoporosis, yet the causes of these associations are unclear6,7,8. An important contributor to this knowledge gap is a limited understanding of the biological differences between women and men surrounding how CVD manifests itself in puberty, pregnancy and menopause9. Addressing heart health at every life stage can improve a woman’s overall health and quality of life. Expanding women’s CVD research by 2040 could lead to at least 1.6 million years of higher-quality life and boost the US economy by $28 billion annually10. More importantly, researching and caring for cardiovascular health should be a priority across a woman’s lifespan, not just at older ages when acute symptoms are most prevalent and most expected by women themselves.

Thus far, multidisciplinary approaches and remote monitoring are being implemented to improve women’s cardiovascular care and outcomes11. One such recent approach is demonstrated by Jasinski et al. in their study titled “A Novel method for quantifying fluctuations in wearable derived daily cardiovascular parameters across the menstrual cycle.” Citing existing research, Jasinski et al. first establish that heart rate variability (a measure of the fluctuation of time between each heartbeat) varies across the menstrual cycle. Jasinski et al. aim to describe the significance of these variations using a novel metric, cardiovascular amplitude. Cardiovascular amplitude is a metric that quantifies that magnitude of heart rate variability and can be routinely measured by wearable technology (wearables)12. Since heart rate variability is a standard feature in most wearables, abstracting the cardiac amplitude is feasible. The authors propose that cardiovascular amplitude may mirror hormonal fluctuations across the female menstrual cycle. They found that cardiovascular amplitude follows a predictable pattern across the menstrual cycle, and they hypothesize that significant fluctuations in cardiovascular amplitude in naturally cycling participants may be due to progesterone increases in the late luteal phase, which are attenuated in individuals who are older or on hormonal birth control. The paper’s results are consistent with existing studies that have shown in anovulatory women with polycystic ovary syndrome, heart rate variability fluctuation is different from normovulatory women throughout the ovulation induction cycles13.

Innovation

Since wearables are currently used for autonomic tracking of fertility and pregnancy status, extending their utility to monitoring cardiovascular variability across the menstrual cycle offers an opportunity to monitor women’s cardiovascular health across the reproductive lifespan and to rapidly identify menstrual irregularities14. The association between cardiovascular amplitude and hormonal fluctuations is useful insofar that it provides a non-invasive way to monitor women’s hormone levels. That can contribute to better cardiovascular health for women by making possible earlier detection of cardiovascular abnormalities. While the data derived from this new metric is promising, more studies are needed to further understand the association between the cardiovascular amplitude values derived in the study and direct measures of hormonal health. On the condition that increasing research validates the accuracy of this new metric and its reliability as a proxy for hormonal fluctuation, access to cardiovascular amplitude on wearables could help users monitor the regularity of their menstrual cycles and take more control of their health.

Challenges

A pressing challenge lies in securing data privacy while also encouraging data interoperability among different wearable brands. The bioethicist Stephanie Morian, in a 2020 study of the terms of service and privacy policies for 15 popular menstruation-tracking applications, found that information about data-sharing practices is often neither easily accessible nor understandable to users15,16. To date, standardized, national regulatory oversight of privacy and data protection policies of menstruation-tracking applications lags behind technological advancements17. While the federal trade commission regulates these applications, the extent of its oversight is not well-defined17. Additionally, as evidenced by a Pew Research Center survey conducted June 3–17, 2019, since approx. 20% of Americans use wearables, higher standards for data privacy, sharing, and security are ethically and legally necessary16.

Conclusion

Jasinski et al. derive a new metric, cardiovascular amplitude, for wearables and suggest that one of its uses could be as a proxy for hormonal fluctuations across the menstrual cycle. That innovation offers clinicians and researchers a window to observe variations in cardiac output at different stages of the menstrual cycle and probe reasons underlying such variations. Equally for users, the novel metric may improve preventive care by way of increasing personal health monitoring. Future studies that substantiate the reliability of this new metric, alongside improved standards for privacy and security of wearables, may bolster the impacts that those technologies can have on women’s cardiovascular health.

Related Articles

Iron homeostasis and ferroptosis in muscle diseases and disorders: mechanisms and therapeutic prospects

The muscular system plays a critical role in the human body by governing skeletal movement, cardiovascular function, and the activities of digestive organs. Additionally, muscle tissues serve an endocrine function by secreting myogenic cytokines, thereby regulating metabolism throughout the entire body. Maintaining muscle function requires iron homeostasis. Recent studies suggest that disruptions in iron metabolism and ferroptosis, a form of iron-dependent cell death, are essential contributors to the progression of a wide range of muscle diseases and disorders, including sarcopenia, cardiomyopathy, and amyotrophic lateral sclerosis. Thus, a comprehensive overview of the mechanisms regulating iron metabolism and ferroptosis in these conditions is crucial for identifying potential therapeutic targets and developing new strategies for disease treatment and/or prevention. This review aims to summarize recent advances in understanding the molecular mechanisms underlying ferroptosis in the context of muscle injury, as well as associated muscle diseases and disorders. Moreover, we discuss potential targets within the ferroptosis pathway and possible strategies for managing muscle disorders. Finally, we shed new light on current limitations and future prospects for therapeutic interventions targeting ferroptosis.

Targeting of TAMs: can we be more clever than cancer cells?

With increasing incidence and geography, cancer is one of the leading causes of death, reduced quality of life and disability worldwide. Principal progress in the development of new anticancer therapies, in improving the efficiency of immunotherapeutic tools, and in the personification of conventional therapies needs to consider cancer-specific and patient-specific programming of innate immunity. Intratumoral TAMs and their precursors, resident macrophages and monocytes, are principal regulators of tumor progression and therapy resistance. Our review summarizes the accumulated evidence for the subpopulations of TAMs and their increasing number of biomarkers, indicating their predictive value for the clinical parameters of carcinogenesis and therapy resistance, with a focus on solid cancers of non-infectious etiology. We present the state-of-the-art knowledge about the tumor-supporting functions of TAMs at all stages of tumor progression and highlight biomarkers, recently identified by single-cell and spatial analytical methods, that discriminate between tumor-promoting and tumor-inhibiting TAMs, where both subtypes express a combination of prototype M1 and M2 genes. Our review focuses on novel mechanisms involved in the crosstalk among epigenetic, signaling, transcriptional and metabolic pathways in TAMs. Particular attention has been given to the recently identified link between cancer cell metabolism and the epigenetic programming of TAMs by histone lactylation, which can be responsible for the unlimited protumoral programming of TAMs. Finally, we explain how TAMs interfere with currently used anticancer therapeutics and summarize the most advanced data from clinical trials, which we divide into four categories: inhibition of TAM survival and differentiation, inhibition of monocyte/TAM recruitment into tumors, functional reprogramming of TAMs, and genetic enhancement of macrophages.

Enhancer reprogramming: critical roles in cancer and promising therapeutic strategies

Transcriptional dysregulation is a hallmark of cancer initiation and progression, driven by genetic and epigenetic alterations. Enhancer reprogramming has emerged as a pivotal driver of carcinogenesis, with cancer cells often relying on aberrant transcriptional programs. The advent of high-throughput sequencing technologies has provided critical insights into enhancer reprogramming events and their role in malignancy. While targeting enhancers presents a promising therapeutic strategy, significant challenges remain. These include the off-target effects of enhancer-targeting technologies, the complexity and redundancy of enhancer networks, and the dynamic nature of enhancer reprogramming, which may contribute to therapeutic resistance. This review comprehensively encapsulates the structural attributes of enhancers, delineates the mechanisms underlying their dysregulation in malignant transformation, and evaluates the therapeutic opportunities and limitations associated with targeting enhancers in cancer.

Photovoltaic bioelectronics merging biology with new generation semiconductors and light in biophotovoltaics photobiomodulation and biosensing

This review covers advancements in biosensing, biophotovoltaics, and photobiomodulation, focusing on the synergistic use of light, biomaterials, cells or tissues, interfaced with photosensitive dye-sensitized, perovskite, and conjugated polymer organic semiconductors or nanoparticles. Integration of semiconductor and biological systems, using non-invasive light-probes or -stimuli for both sensing and controlling biological behavior, has led to groundbreaking applications like artificial retinas. From fusion of photovoltaics and biology, a new research field emerges: photovoltaic bioelectronics.

Emerging insights in senescence: pathways from preclinical models to therapeutic innovations

Senescence is a crucial hallmark of ageing and a significant contributor to the pathology of age-related disorders. As committee members of the young International Cell Senescence Association (yICSA), we aim to synthesise recent advancements in the identification, characterisation, and therapeutic targeting of senescence for clinical translation. We explore novel molecular techniques that have enhanced our understanding of senescent cell heterogeneity and their roles in tissue regeneration and pathology. Additionally, we delve into in vivo models of senescence, both non-mammalian and mammalian, to highlight tools available for advancing the contextual understanding of in vivo senescence. Furthermore, we discuss innovative diagnostic tools and senotherapeutic approaches, emphasising their potential for clinical application. Future directions of senescence research are explored, underscoring the need for precise, context-specific senescence classification and the integration of advanced technologies such as machine learning, long-read sequencing, and multifunctional senoprobes and senolytics. The dual role of senescence in promoting tissue homoeostasis and contributing to chronic diseases highlights the complexity of targeting these cells for improved clinical outcomes.

Responses

Your email address will not be published. Required fields are marked *